# OnCo record bispecific-adc (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/bispecific-adc/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "bispecific-adc" ;
  schema:name "Bispecific ADC"@en ;
  schema:description "A bispecific ADC is an ADC whose antibody grabs two different proteins on the cancer cell, so it sticks better to tumour and less to healthy tissue."@en ;
  schema:url <https://onco.cc/technologies/bispecific-adc/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06382142>, <https://clinicaltrials.gov/study/NCT06304974> ;
  onco:status "phase-3" ;
  onco:tag "frontier" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/urothelial/> ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/nectin4/>, <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/b7h3/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/tilatamig-samrotecan/>, <https://onco.cc/drugs/ak146d1/> ;
  onco:companies <https://onco.cc/companies/systimmune/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/akeso/>, <https://onco.cc/companies/avenzo/>, <https://onco.cc/companies/valink-therapeutics/> ;
  onco:dependsOn <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bispecific-antibody/> .